Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach

Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach

Microfluidics has provided clinicians with new technologies to detect and analyze circulating tumor biomarkers in order to further improve their understanding of disease mechanism, as well as to improve patient management. Among these different biomarkers, circulating tumor cells have proven to be o...

Full description

Bibliographic Details
Main Authors:	Ezgi Tulukcuoglu Guneri, Emile Lakis, Ismail Hajji, Elian Martin, Jerome Champ, Aurore Rampanou, Jean-Yves Pierga, Jean-Louis Viovy, Charlotte Proudhon, François-Clément Bidard, Stéphanie Descroix
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	Cancers
Subjects:	circulating tumor cells proximity ligation assay HER2 HER3 dimerization microfluidic
Online Access:	https://www.mdpi.com/2072-6694/14/8/1890

Similar Items

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases
by: Malcolm Lim, et al.
Published: (2022-01-01)

Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma
by: Giovanni Almadori, et al.
Published: (2021-09-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma
by: Paula González-Alonso, et al.
Published: (2015-08-01)

Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications
by: Ana Godoy-Ortiz, et al.
Published: (2019-10-01)

A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells
by: Hamid Maadi, et al.
Published: (2022-12-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

Editorial: Cancer Treatment and Early Detection Targeting HER Receptors
by: Xiaoqing Cai, et al.
Published: (2022-06-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-05-01)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
by: Yuxin Mu, et al.
Published: (2023-12-01)

Ultrasensitive assay of HER1, HER2, and heregulin-α in whole blood
by: Raluca-Ioana Stefan-van Staden, et al.
Published: (2022-12-01)

Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation
by: Raphael Trenker, et al.
Published: (2024-03-01)

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
by: Tejaswini P. Reddy, et al.
Published: (2020-05-01)

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers
by: Elizabeth Rubin, et al.
Published: (2024-01-01)

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
by: Lena-Christin Conradi, et al.
Published: (2019-09-01)

Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells
by: Lisandra Negrón-Vega, et al.
Published: (2022-09-01)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
by: Guo-dong Cao, et al.
Published: (2017-12-01)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
by: Mengyuan Cai, et al.
Published: (2023-07-01)

Editorial: Cancer treatment and early detection targeting HER receptors, Volume II
by: Xiaoqing Cai, et al.
Published: (2023-06-01)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
by: Laura Morsberger, et al.
Published: (2022-11-01)

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface
by: Jeroen Claus, et al.
Published: (2018-05-01)

Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models
by: Emilia Rabia, et al.
Published: (2021-01-01)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
by: Jing Ma, et al.
Published: (2022-07-01)

HER2-positive breast cancer – Available anti-HER2 therapies and new agents under investigation
by: Martyna Zielińska, et al.
Published: (2020-06-01)

HER2 c-Terminal Fragments Are Expressed via Internal Translation of the HER2 mRNA
by: Jack D. Godfrey, et al.
Published: (2022-08-01)

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
by: Patrik Pöschke, et al.
Published: (2023-09-01)

The potential of panHER inhibition in cancer
by: Xiaochun eWang, et al.
Published: (2015-01-01)

Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses
by: Insu Jeon, et al.
Published: (2020-07-01)

Frequency of HER-2 over Expression in the Patients with Breast Cancer after Mastectomy
by: S kargar, et al.
Published: (2013-10-01)

Development of Electrochemical Immunosensors for HER-1 and HER-2 Analysis in Serum for Breast Cancer Patients
by: Shayalini Wignarajah, et al.
Published: (2023-03-01)

Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
by: Lin-Yu Xia, et al.
Published: (2024-04-01)

Minimal HER1 and HER2 expressions in CHO and HEK-293 cells cause them appropriate negative cells for HERs-related studies
by: Abasalt Hosseinzadeh Colagar, et al.
Published: (2013-11-01)

A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China
by: Shuling Zhou, et al.
Published: (2023-01-01)

HER2-/HER3-Targeting Antibody—Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors
by: Kimio Yonesaka
Published: (2021-03-01)

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies
by: Gretchen Bergado-Báez, et al.
Published: (2022-11-01)

Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer
by: Katrin Almstedt, et al.
Published: (2023-02-01)

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
by: Chiara Tommasi, et al.
Published: (2024-03-01)

A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
by: Alexander Rau, et al.
Published: (2021-01-01)